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Glutathione S-transferases (GSTs) are phase II drug detoxifying enzymes that play an
essential role in the maintenance of cell integrity and protection against DNA damage
by catalyzing the conjugation of glutathione to a wide variety of exo- and endogenous elec-
trophilic substrates. Glutathione S-transferase P1 (GSTP1), the gene encoding the pi-class
GST, is frequently inactivated by acquired somatic CpG island promoter hypermethylation in
multiple cancer subtypes including prostate, breast, liver, and blood cancers. Epigenetically
mediated GSTP1 silencing is associated with enhanced cancer susceptibility by decreasing
its “caretaker” gene function, which tends to promote neoplastic transformation allowing
cells to acquire additional alterations. Thus, this epigenetic alteration is now considered as
a cancer biomarker but could as well play a driving role in multistep cancer development,
especially well documented in prostate cancer development.The present review discusses
applications of epigenetic alterations affecting GSTP1 in cancer medicine used alone or in
combination with other biomarkers for cancer detection and diagnosis as well as for future
targeted preventive and therapeutic interventions including by dietary agents.
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INTRODUCTION
As one of the driving forces behind the cellular detoxiﬁcation
machinery, glutathione S-transferases (GSTs) and especially the
pi class glutathione S-transferase P1 (GSTP1) is currently in the
focus of the cancer research community, evaluating the relevance
of GSTP1 epimutations for cancer development and its potential
as a major epigenetic cancer biomarker.
The human GST multi-gene superfamily is encoding for vari-
ous ubiquitous cytosolic or soluble, mitochondrial and microso-
mal as well as peroxisomal homo- and heterodimeric transferases
(Di Pietro et al., 2010). Despite themultifunctionality of these pro-
teins,GSTs are best known for their ability to transfer the tripeptide
gamma-glutamyl-cysteinyl-glycine, also known as glutathione
(GSH) to a wide variety of highly genotoxic and cell-damaging
molecules, either directly occurred from the extracellular envi-
ronment or from the intracellular detoxiﬁcation metabolism. In
most albeit not all cases, glutathione S-conjugation generates a
less or non-toxic product with improved water solubility, favoring
the exportation out of the cell and thereby contributing to DNA
damage prevention and protection of the cellular integrity (Baden
et al., 2011). Moreover, several GST isozymes are implicated in cell
signaling, interfering for example with the MAPK signaling cas-
cade, which is involved in the regulation of cell cycle, proliferation
and cell death (Wang et al., 2001; Laborde, 2010).
Regardless the importance of GST activity for cellular vitality
and health, the GST gene cluster is a hotspot for DNA sequence
mutations that leads to the expression of active but function-
ally different GST variant proteins. Accordingly, cells expressing
less active GST isoforms are more sensible to GST-metabolized
toxins compared to cells with balanced GST activity. In a worst
case-scenario, cells are incapable to degrade carcinogens or stress-
induced toxic intermediates, thus increasing their susceptibility to
undergo further steps toward cancer progression or event other
diseases (Deep et al., 2012). The GSTP1∗B (Val105) allele is often
mentionedwithin the context of genetic polymorphisms, a GSTP1
variation which is characterized by an A→G sequence transition
in codon 105 of exon 5, leading to the exchange of isoleucine by
valine, thus decreasing its catalytic activity associatedwith reduced
cell detoxiﬁcation ability (Saxena et al., 2012).
IMPORTANCE OF GLUTATHIONE S -TRANSFERASE P1 CLASS
IN CANCER DEVELOPMENT
Furthermore, the previously mentioned cytosolic GSTP1 isoen-
zyme consist of one of the best-studied variants of the GST
metabolism. Located on chromosome 11, the GSTP1 coding
region is controlled by a large CpG island (CGI) upstream of the
transcription start site in the promoter region. Both areas are sepa-
rated by a longATAAA repetitive stretch, which probably acts as an
insulator to separate different epigenetic states such asmethylation
of the CGIs (Millar et al., 2000). Moreover, various transcription
factors such as speciﬁcity protein 1 (SP1), activator protein 1 (AP-
1), nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) and GATA1 were reported to play an important role in
the regulation of GSTP1 expression (Figure 1; Moffat et al., 1996;
Duvoix et al., 2003b, 2004b; Schnekenburger et al., 2003; Morceau
et al., 2004).
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FIGURE 1 | Glutathione S-transferase P1 (GSTP1) regulatory elements.
This scheme depicts essential transcriptional regulatory elements known to
regulate GSTP1 gene expression. Proximal promoter region contains (i) two
SP1 sites (Morrow et al., 1989), (ii) oneTPA-response element (TRE) binding
(activator protein) AP-1 and nuclear factor, erythroid 2 (NF-E2) depending on
the cellular environment (Borde-Chiche et al., 2001b; Duvoix et al., 2003a,b,
2004a,b), (iii) one nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) binding site (Morceau et al., 2004), and (iv) a GATA-1 binding site
(Schnekenburger et al., 2003, 2004). Figure was generated by using
ScienceSlides.
Glutathione S-transferase P1 is also involved in cell death
regulation, interacting with apoptotic signaling pathways as for
example c-Jun NH2-terminal kinase (JNK1), ERK1/ERK2, or
tumor necrosis factor receptor-associated factor 2 (TRAF2; Ruscoe
et al., 2001; Wu et al., 2006). In correlation to its biotransforma-
tion and detoxiﬁcation ability, GSTP1 is expressed in most cells
and particularly in those that are in contact with the external envi-
ronment such as cells of the urinary, digestive, and respiratory
tract (Terrier et al., 1990; Yuan et al., 2008).
Increased levels of GSTP1 expression can also be indicative for
enhanced detoxiﬁcation activity due to xeno- or endo-biotic expo-
sure implicating oxidative stress (Kanwal et al., 2014). Accordingly,
increased GSTP1 expression is often detected in many cancers
(e.g., breast, colon, stomach, pancreas, bladder, lung, head and
neck, ovary and cervix, soft tissue sarcoma, testicular embry-
onic carcinoma, meningioma, and glioma), which is associated
to enhanced detoxiﬁcation activity, thus protecting cancer cells
against cytotoxic and cytostatic drugs (Ruzza et al., 2009). In con-
trast, knockout experiences in mice showed that loss of GSTP1
expression leads to increased cancer susceptibility (Henderson
et al., 1998; Ketterer, 1998).
REGULATION OF CELLULAR ACTIVITIES THROUGH
EPIGENETIC MECHANISMS
Alterations in the epigenetic setup are as important as genetic
aberrations and may cooperate in cancer genesis. While classical
gene mutations are region-limited, epimutations often occur early
in cancer development and have a genome-wide impact, boosting
on the one hand the expression of cell survival genes or proto-
oncogenes and deactivating on the other hand tumor suppressor
genes (TSGs), DNA repair mechanisms as well as cell division
brakes, thus leading to carcinogenesis (Esteller, 2008; Florean et al.,
2011; Karius et al., 2012; Schnekenburger and Diederich, 2012;
Seidel et al., 2012; Blancafort et al., 2013).
In addition to the genetic information encoded by the primary
DNA sequence, epigenetic mechanisms add a layer of regula-
tion of the information and includes DNA methylation, histone
modiﬁcations as well as regulation by non-coding RNAs (Esteller,
2008; Florean et al., 2011; Karius et al., 2012; Schnekenburger and
Diederich, 2012; Seidel et al., 2012; Blancafort et al., 2013). This
interacting cluster of epigenetic regulators provides an epigenetic
memory, transferring epigenetic information through mitotic and
meiotic cell divisions (Migicovsky and Kovalchuk, 2011). These
reversible modiﬁcations are playing essential roles in gene regula-
tion, X-inactivation, imprinting, and silencing of parasitic DNA
elements (Jaenisch and Bird, 2003).
PATHOLOGICAL ALTERATIONS OF GSTP1 METHYLATION PATTERNS
DNA methylation, the addition of a methyl-group to cytosines
is the most common epigenetic modiﬁcation, inducing the reor-
ganization of the gene locus and thus regulating gene expression
(Smith and Meissner, 2013). However, tumor cells typically pos-
sess an aberrant methylation pattern associated with altered gene
expression proﬁles, showing locally restricted hypermethylation of
individual promoter regions involved in the silencing of TSGs. At
the same time, genome-wide loss of DNA methylation is observed
in tumor cells compared to healthy cells inducing chromosomal
instability, loss of imprinting as well as the previously described
oncogene activation.
In its function as a cellular “caretaker”, attenuation of GSTP1
expression or activity by either genetic (e.g., deletion or muta-
tion) or epigenetic alterations may reduce cellular detoxiﬁcation
capacity (Figure 2). In fact, the use of GSTP1 knockout mice
demonstrated that loss of GSTP1 expression increases sensitivity
to metabolic or environmental toxins and promotes mutations
and cancer development (Coughlin and Hall, 2002a,b).
Prostate cancer
Promoter hypermethylation leading to epigenetic silencing of
GSTP1 gene expression is frequently detected in prostate can-
cer cells, the most commonly diagnosed type of malignancy
among men in Western European countries and the second cause
of cancer-related deaths among men worldwide (Brooks et al.,
1998; Cairns et al., 2001; Jeronimo et al., 2002; Henrique and
Jeronimo, 2004; Dumache et al., 2010; Ferlay et al., 2010). Interest-
ingly, GSTP1 hypermethylation is strictly restricted to malignant
cells including prostate cancer cells (PCa) as well as prostatic
intraepithelial neoplasia (PIN). Detection of GSTP1 methylation
in all types of body ﬂuids of prostate cancer patients represents
a promising epigenetic biomarker, which is already under eval-
uation for the application of new prognostic methods (Cairns
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FIGURE 2 | Hypermethylation of the glutathione S-transferase P1
promoter as early cancer biomarker. Environmental exposure leads to
progressive methylation of CpG islands (CGI) at the GSTP1 promoter
region. The resulting decreased cell detoxiﬁcation capacity leads to
increased genotoxic stress and progressive accumulation of additional
genetic alterations accompanied by an increased proliferation rate. DNA
methylation analysis of the GSTP1 promoter in body ﬂuids allows
detecting progressive hypermethylation and turns this molecular feature
into a valid early cancer biomarker. Figure was generated by using
ScienceSlides.
et al., 2001; Esteller, 2008; Yang and Park, 2012; Figure 2).
In contrast, GSTP1 promoter remains almost unmethylated
in benign lesions, allowing distinguishing benign and cancer-
ous transformations (Hopkins et al., 2007; Cao and Yao, 2010).
Recently, Re et al. (2011) published that, beyond hypermethyla-
tion, chromatin remodeling by a combinatorial complex between
estrogen receptor (ER) and endothelial nitric oxide synthase
(eNOS) also represses transcription of prognostic genes that are
down-regulated in PCa, such as GSTP1. In PCa cultured cells
ER/eNOS causes GSTP1 repression by being recruited at estro-
gen responsive elements within its promoter favoring a local
chromatin remodeling together with hypermethylated promoter
sequences.
Lung cancer
Esteller et al. (1999) published that aberrant hypermethyla-
tion of the TSG p16, the putative metastasis suppressor gene
death-associated protein kinase (DAPK), GSTP1, and the DNA
repair gene O6-methylguanine-DNA-methyltransferase (MGMT)
is observed in non-small cell lung cancer (NSCLC) tumors but
not in any paired normal lung tissue. In primary tumors with
methylation, 11 of 15 (73%) samples also had abnormal methy-
lated DNA in the matched serum samples. More recently, Kim
et al. (2005) concluded that DNA methylation status of CGI could
be used as a predictor of long-term outcome for adenocarcinoma
of the lung.
Leukemia and lymphoma
Borde-Chiche et al. (2001a) published that methylation of CpG
sites of the basal GSTP1 promoter is an essential mecha-
nism controlling GSTP1 gene expression in human leukemia.
Karius et al. (2011) further investigated this mechanism and
showed by bisulﬁte sequencing, methylation-speciﬁc PCR and
combined bisulﬁte restriction analysis that the GSTP1 promoter
was completely methylated in transcriptionally inactive in RAJI
Burkitt’s lymphoma and MEG-01 chronic myeloid leukemia cell
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lines. In contrast, cell lines expressing GSTP1 exhibited an
unmethylated and transcriptionally active promoter thus conﬁrm-
ing a relationship between hypermethylation and repression of
GSTP1 expression (Karius et al., 2011).
Rossi et al. (2004) investigated methylation of MGMT, DAPK,
and GSTP1 and concluded that these alterations represent a major
pathogenetic event in several B-cell malignancies. Inactivation of
GSTP1 in gastricMALT lymphoma represents an additionalmech-
anism favoring accumulation of reactive oxygen species to further
promote lymphomagenesis. Finally, frequency of GSTP1 aberrant
methylation in diffuse large B-cell lymphoma (DLBCL) also led to
studies to validate the prognostic impact of such epigenetic alter-
ation in these lymphomas. Nakamichi et al. (2007) established a
correlation between promoter hypermethylation of GSTP1 and
response to chemotherapy in DLBCL. According to the authors,
the GSTP1 gene methylation status could be an indicator of drug
response and a prognosticator forDLBCL (Nakamichi et al., 2007).
Breast cancer
Jhaveri and Morrow initially published that methylation status
of GSTP1 promoter contributes signiﬁcantly to the levels of
GSTP1 expressed in ER-negative and ER+-positive breast can-
cer cell lines (Jhaveri and Morrow, 1998). Moreover, GSTP1
hypermethylation and therefore gene silencing was associated
to increased grades of mammary phyllodes tumors. As such
GSTP1 methylation patterns allow distinguishing two groups: one
benign unmethylated group as well as samples presenting hyper-
methylated GSTP1 gene promoters in the borderline/malignant
tumor group (Kim et al., 2009). Recently, Miyake et al. (2012)
demonstrated that GSTP1 expression predicts poor patholog-
ical complete response to neoadjuvant chemotherapy in ER-
negative breast cancer. Indeed, GSTP1 expression can predict
pathological response to chemotherapeutic treatments with 5-
ﬂuorouracil/epirubicin/cyclophosphamide in ER-negative tumors
but not in ER-positive tumors. Additionally, GSTP1 promoter
hypermethylation might be implicated more importantly in the
pathogenesis of luminalA, luminal B, andHER2-enriched tumors,
than in basal-like tumors.
Liver cancer
According to Zhang et al. (2012) GSTP1 is transcriptionally
silenced by promoter hypermethylation in several human can-
cer types including hepatocellular carcinoma (HCC). These
results suggest that epigenetic inactivation of GSTP1 plays an
important role in the development of HCC and exposure to
environmental carcinogens may be related to altered methy-
lation of genes involved in hepatocarcinogenesis (Zhang et al.,
2012).
Other cancer subtypes
Similarly, the invasion potential of pituitary tumors and endome-
trial carcinomas was linked to reduction of GSTP1 expression
and methylation frequency, indicating that epigenetically medi-
ated down-regulation of GSTP1 expression may also contribute to
aggressive pituitary tumor behavior (Chan et al., 2005; Yuan et al.,
2008).
PATHOLOGICAL ALTERATIONS OF GSTP1 METHYLATION PATTERNS
Beyond DNA hypermethylation, which was the ﬁrst epigenetic
alteration to be discovered as an inﬂuencing factor for GSTP1
expression, histone modiﬁcations were discovered in the early
2000 s to play a regulating role in GSTP1 expression. Moreover, an
interplay between histone reprogramming and DNA methylation
was emerging. Bakker et al. (2002) initially showed that methyl-
CpG binding domain protein (MBD)2 represses transcription
from hypermethylated GSTP1 gene promoters in HCC cells con-
necting hypermethylation and reduced transactivation potential.
Similarly, Lin and Nelson (2003) published that MDB2 medi-
ates transcriptional repression associated with hypermethylated
GSTP1 CGIs in MCF-7 breast cancer cells.
HATs (histone acetyltransferases) contribute to the regula-
tion of gene expression, and loss or deregulation of these
activities may link to tumorigenesis. Ohta et al. (2007) demon-
strated that expression levels of HATs, p300, and CBP
[CREB (cAMP-response-element-binding protein)-binding pro-
tein] were decreased during chemical hepatocarcinogenesis,
whereas expression of MOZ (monocytic leukemia zinc-ﬁnger
protein; MYST3), a member of the MYST [MOZ, Ybf2/Sas3,
Sas2, and TIP60 (Tat-interacting protein, 60 kDa)] HAT family
was induced. Exogenous MOZ induced GSTP1 expression in rat
hepatoma H4IIE cells. These results suggest that during early hep-
atocarcinogenesis, aberrantly expressed MOZ may induce GSTP1
expression through the NF-E2-related factor 2 (Nrf2)-mediated
pathway.
Okino et al. (2007) investigated chromatin changes on GSTP1
promoter associated with its inactivation in prostate cancer.
Thus, treatment of LNCaP cells with the DNA demethylating
agent 5-azacytidine also restored activating histone modiﬁca-
tions on GSTP1 and as a result reactivated transcription. Authors
concluded that, in the process of prostate carcinogenesis, activat-
ing histone modiﬁcations on GSTP1 are lost and subsequently
DNA becomes methylated and inaccessible resulting in transcrip-
tional silencing thus demonstrating interplay between histone
reprogramming and promoter region methylation (Okino et al.,
2007).
Karius et al. (2011) further contributed that histone marks
and effector proteins associated with transcriptional activity
could be detected by chromatin immunoprecipitation in GSTP1
expressing hypomethylated K-562 cell line. However, repres-
sive chromatin marks and the recruitment of silencing protein
complexes were found in the non-expressing hypermethylated
RAJI and MEG-01 cell lines, again validating the interrelation-
ship between DNA methylation and histone marks (Karius et al.,
2011).
In prostate cancer cells, Hauptstock et al. (2011) used the
histone deacetylase inhibitor depispeptide to reverse DNA hyper-
methylation and alter the histone modiﬁcation pattern at GSTP1
promoter, including a reduction of H3K9me2/3 and H3K27me2/3
and an increase of H3K18Ac, thereby inducing GSTP1 mRNA
re-expression. For these authors, successful therapy requires both,
DNA demethylation and triggering activating histone modiﬁ-
cations, to induce complete gene expression of epigenetically
silenced genes and depsipeptide fulﬁlls both criteria (Hauptstock
et al., 2011).
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SMALL REGULATORY RNA INVOLVED IN GSTP1 EXPRESSION
MicroRNAs (miRNAs) constitute a large family of regulatory non-
coding (nc)RNAs (Morceau et al., 2013). These single stranded
RNAs (17–25 nucleotides) are highly conserved during evolution
and are generated by amultistage process. Their expression leads to
post-transcriptional silencing of target genes bymRNA translation
repression. MiRNAs target several mRNAs while a speciﬁc mRNA
can be targeted by several miRNAs. Altogether these regulatory
mechanisms also belong to epigenetic regulation.
Accumulating evidence suggest that, as most mRNAs, the level
of GSTP1 transcripts can potentially be regulated by several miR-
NAs. Patron et al. (2012) published that miR-133b reduces GSTP1
expression by 2.1 fold in prostate cancer cells. In addition, miR-
513a-3p sensitizes human A549 lung adenocarcinoma cells to
chemotherapy by targeting GSTP1 (Zhang et al., 2012). Mutal-
lip et al. (2011) showed that transient transfection of miR-133a
repressed the expression of GSTP1 at mRNA and protein levels.
Similar results were published in human bladder cancer (Uchida
et al., 2013) and earlier in lung squamous cell carcinoma (Moriya
et al., 2012).
Even though only limited information is available regarding the
regulation of GSTP1 by miRNAs, we believe that further investi-
gations could contribute to the development of new therapeutic
miRNA-based anticancer strategies.
DIETARY REGULATORS OF GSTP1 EXPRESSION
Since progressive GSTP1 hypermethylation is a hallmark
biomarker but potentially also a driver of prostate cancer progres-
sion, various research teams were looking for dietary intervention
to lower the methylation burden of GSTP1 gene promoter. By
re-expressing GSTP1, increased detoxiﬁcation, and reduced levels
of oxidative stress could potentially contribute to reduced prostate
cancer progression and even to an abrogation on evolution toward
invasive and metastatic disease.
Accordingly, many studies reported dietary nutrients or phyto-
chemicals that present the potential to restore GSTP1 expression
(Schnekenburger et al., 2014). For instance, Vardi et al. (2010)
showed that soy phytoestrogens modify DNA methylation of
GSTP1, RASSF1A, EPH2, and BRCA1 TSG promoters in prostate
cancer cells. After treatment by phytoestrogens, demethylation
of GSTP1, and EPHB2 promoter regions was observed and an
increase in their protein expression levels was demonstrated by
immunohistochemistry. Altogether epigenetic modiﬁcations of
DNA, such as the promoter CGI demethylation of TSGs, might
be related to the protective effect of soy on prostate cancer (Vardi
et al., 2010). In prostate cancer cells, phenethyl isothiocyanate,
a phytochemical found in large amounts in cruciferous vegeta-
bles, was reported to restore expression of silenced GSTP1 by
a mechanism involving promoter demethylation and increased
histone acetylation. These effects are associated with increased
expression of the cyclin-dependent kinase inhibitors (CDKNs)
p21 and p27, which are negative cell cycle regulators (Huang
et al., 2011). Furthermore, it was established that GSTP1 gene
was demethylated and reactivated following exposure to green
tea polyphenols in prostate cancer cells (Pandey et al., 2010).
Interestingly, lycopene also reactivated GSTP1 gene expression
through reduced promoter methylation in MDA-MB-468 breast
cancer cells (King-Batoon et al., 2008). In rodents, choline deﬁ-
ciency results in global hypomethylation of hepatic DNA and
aberrant DNA hypermethylation at targeted TSG promoters such
as of the GSTP1 gene promoter (Zeisel, 2012). Finally, Xiang
et al. (2008) published that selenite (Se) treatment decreased
general DNA methylation and caused partial promoter demethy-
lation and re-expression of the TSGs adenomatous polyposis
coli (APC) and cellular stress response 1, a gene involving
tumor growth and metastasis. This study demonstrates that
Se can epigenetically modulate DNA and histones to activate
methylation-silenced genes. These epigenetic modiﬁcations may
altogether contribute to cancer prevention by Se (Xiang et al.,
2008).
CONCLUSIVE REMARKS
Considering that the discrimination power of serum prostate-
speciﬁc antigen (PSA) measurement between benign and malig-
nant tumor cells is currently under controversial discussion, the
best and the most promising epigenetic marker for prostate cancer
detection is the hypermethylation of GSTP1.
The previously mentioned speciﬁcity for prostate intraepithe-
lial neoplasia allows differentiating from unmethylated benign
hyperplastic prostate tissue, which always remains unmethylated.
Moreover, many tumors including PCa cells shed DNA into the
serum or other easily accessible body ﬂuids (e.g., semen, urine),
simplifying the detection of GSTP1 epimutations in early tumori-
genesis stages. Indeed, early presence of hypermethylated TSGs
does not necessarily indicate an invasive cancer, as premalignant or
cancer precursor lesions can also carry these epigenetic signatures.
Hence, these signatures, including miRNAs, could be used for
early cancer detection in individuals with genetic predispositions
or exposed to carcinogens.
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